Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort: An ECCO-EpiCom Study

Background:No direct comparison of health care cost in patients with inflammatory bowel disease across the European continent exists. The aim of this study was to assess the costs of investigations and treatment for diagnostics and during the first year after diagnosis in Europe. Methods:The EpiCom cohort is a prospective population-based inception cohort of unselected inflammatory bowel disease patients from 31 Western and Eastern European centers. Patients were followed every third month from diagnosis, and clinical data regarding treatment and investigations were collected. Costs were calculated in euros (&OV0556;) using the Danish Health Costs Register. Results:One thousand three hundred sixty-seven patients were followed, 710 with ulcerative colitis, 509 with Crohn's disease, and 148 with inflammatory bowel disease unclassified. Total expenditure for the cohort was &OV0556;5,408,174 (investigations: &OV0556;2,042,990 [38%], surgery: &OV0556;1,427,648 [26%], biologicals: &OV0556;781,089 [14%], and standard treatment: &OV0556;1,156,520 [22%)]). Mean crude expenditure per patient in Western Europe (Eastern Europe) with Crohn's disease: investigations &OV0556;1803 (&OV0556;2160) (P = 0.44), surgery &OV0556;11,489 (&OV0556;13,973) (P = 0.14), standard treatment &OV0556;1027 (&OV0556;824) (P = 0.51), and biologicals &OV0556;7376 (&OV0556;8307) (P = 0.31). Mean crude expenditure per patient in Western Europe (Eastern Europe) with ulcerative colitis: investigations &OV0556;1189 (&OV0556;1518) (P < 0.01), surgery &OV0556;18,414 (&OV0556;12,395) (P = 0.18), standard treatment &OV0556;896 (&OV0556;798) (P < 0.05), and biologicals &OV0556;5681 (&OV0556;72) (P = 0.51). Conclusions:In this population-based unselected cohort, costs during the first year of disease were mainly incurred by investigative procedures and surgeries. However, biologicals accounted for >15% of costs. Long-term follow-up of the cohort is needed to assess the cost-effectiveness of biological agents.

[1]  C. O'Morain,et al.  Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with inflammatory bowel disease--an ECCO-EpiCom study. , 2014, Journal of Crohn's & colitis.

[2]  C. O'Morain,et al.  Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe: The ECCO-EpiCom Cohort , 2014, Inflammatory bowel diseases.

[3]  J. Burisch.  Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort. , 2014, Danish medical journal.

[4]  A. Menter,et al.  Burden of Disease: Psoriasis and Psoriatic Arthritis , 2013, American Journal of Clinical Dermatology.

[5]  P. Lakatos,et al.  The burden of inflammatory bowel disease in Europe. , 2013, Journal of Crohn's & colitis.

[6]  N. Pedersen,et al.  East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort , 2013, Gut.

[7]  S. Vermeire,et al.  Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. , 2012, Journal of Crohn's & colitis.

[8]  M. V. van Oijen,et al.  Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study , 2012, Gut.

[9]  C. O'Morain,et al.  Sa1256 Cost-Effectiveness of Episodic or Maintenance Infliximab Treatment Versus Standard Treatment in a Community-Based Incidence Cohort of Adult Ulcerative Colitis Patients With 10-Years Follow-up , 2012 .

[10]  G. Veres,et al.  Has There Been a Change in the Natural History of Crohn's Disease? Surgical Rates and Medical Management in a Population-Based Inception Cohort from Western Hungary Between 1977–2009 , 2012, The American Journal of Gastroenterology.

[11]  C. O'Morain,et al.  P254 Effect of standard treatment (ST) versus episodic (ET) or maintenance (MT) infliximab on healthcare cost (HC) and quality-adjusted life years (QALYs) in a community-based incidence cohort of adult Crohn's disease patients with 10 years follow-up , 2012 .

[12]  R. Goeree,et al.  Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease. , 2012, Journal of Crohn's & colitis.

[13]  S. Vermeire,et al.  Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European Collaborative follow-up study. , 2011, Journal of Crohn's & colitis.

[14]  V. Andersen,et al.  Construction and validation of a web-based epidemiological database for inflammatory bowel diseases in Europe An EpiCom study. , 2011, Journal of Crohn's & colitis.

[15]  A. Ford,et al.  Costs of care for Crohn’s disease following the introduction of infliximab: a single‐centre UK experience , 2010, Alimentary pharmacology & therapeutics.

[16]  Mark Atkinson,et al.  Estimating the Cost of Type 1 Diabetes in the U.S.: A Propensity Score Matching Method , 2010, PloS one.

[17]  J. Chao,et al.  Systematic review: the costs of ulcerative colitis in Western countries , 2010, Alimentary pharmacology & therapeutics.

[18]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.

[19]  Laurent Beaugerie,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. , 2006, Journal of Crohn's & colitis.

[20]  E. Finkelstein,et al.  Annual medical spending attributable to obesity: payer-and service-specific estimates. , 2009, Health affairs.

[21]  S. Hanauer,et al.  Management of Crohn's Disease in Adults , 2001, The American Journal of Gastroenterology.

[22]  S. Odes,et al.  How expensive is inflammatory bowel disease? A critical analysis. , 2008, World journal of gastroenterology.

[23]  C. O'Morain,et al.  Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. , 2006, Gastroenterology.

[24]  P. Munkholm,et al.  Increasing Incidences of Inflammatory Bowel Disease and Decreasing Surgery Rates in Copenhagen City and County, 2003–2005: A Population-Based Study from the Danish Crohn Colitis Database , 2006, The American Journal of Gastroenterology.

[25]  S. Auvin,et al.  Incidence, Clinical Presentation and Location at Diagnosis of Pediatric Inflammatory Bowel Disease: A Prospective Population-Based Study in Northern France (1988-1999) , 2005, Journal of pediatric gastroenterology and nutrition.

[26]  S. Travis,et al.  Guidelines for the management of inflammatory bowel disease in adults , 2004, Gut.

[27]  Shivananda,et al.  EC-IBD: a European effort in inflammatory bowel disease. , 2000, European journal of internal medicine.

[28]  C. Bernstein,et al.  Direct hospital costs for patients with inflammatory bowel disease in a Canadian Tertiary Care University Hospital , 2000, American Journal of Gastroenterology.

[29]  R. Cohen,et al.  The cost of hospitalization in Crohn's disease , 2000, American Journal of Gastroenterology.

[30]  E. Langholz.  Ulcerative colitis. An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosis. , 1999, Danish medical bulletin.

[31]  A. Zinsmeister,et al.  Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. , 1999, Gastroenterology.

[32]  P. Munkholm.  Crohn's disease--occurrence, course and prognosis. An epidemiologic cohort-study. , 1997, Danish medical bulletin.

[33]  J. Lennard-jones,et al.  Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. , 1997, European journal of gastroenterology & hepatology.

[34]  P. Munkholm,et al.  Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. , 1997, Scandinavian journal of gastroenterology.

[35]  P. Freeny,et al.  Crohn's disease and ulcerative colitis. Evaluation with double-contrast barium examination and endoscopy. , 1986, Postgraduate medicine.